期刊文献+

HLA-G在异基因造血干细胞移植中诱导免疫耐受 被引量:4

Role of membrane-bound human leukocyte antigen G in inducing immune tolerance after allogeneic hematopoietic stem cell transplantation
暂未订购
导出
摘要 目的研究供者粒细胞集落刺激因子(G-CSF)动员前后外周血和骨髓中单个核细胞人白细胞分化抗原G(HLA-G)膜表达以及血浆和骨髓液中HLA-G水平,揭示G-CSF动员骨髓移植优于外周血干细胞移植与骨髓中HLA-G有关的机制。方法流式细胞术检测外周血和骨髓中单个核细胞HLA-G膜表达以及酶联免疫吸附法(ELISA)检测血浆和骨髓液中HLA-G水平。结果动员后膜结合型HLA-G(mHLA-G)在外周血和骨髓中均显著高于动员前(P=0.001,P=0.000),且动员后骨髓mHLA-G含量较外周血中高(P=0.001)。动员后外周血中分泌型HLA-G(sHLA-G)较动员前无明显差异(P=0.279),动员后骨髓中sHLA-G较动员前明显增高(P=0.002),且动员后骨髓sHLA-G较动员后外周血中含量明显增高(P=0.004)。结论HLA-G在G-CSF动员后造血干细胞移植(HSCT)诱导免疫耐受中具有重要作用。 Objective To evaluate the role of human leukocyte antigen G (HLA-G) in the better effect of allogenetic bone marrow transplantation than that of peripheral blood stem cell transplantation. Methods Flow cytometry was used to detect the expression of membrane-bound HLA-G (mHLA-G) on donor peripheral blood (PBC) or bone marrow (BM) mononuclear cells. The levels of soluble HLA-G (sHLA-G) in the plasma and bone marrow fluid were determined using enzyme-linked immunosorbent assay (ELISA) before and after granuloeyte colony-stimulating factor (G-CSF) mobilization. Results The mean levels of mHLA-G after G-CSF mobilization in the PBC and BM were significantly higher than that before G-CSF mobilization (P=0.001 and 0.000), but the plasma levels of sHLA-G showed no significant changes after the mobilization (P=0.279). The mean levels of sHLA-G in the BM fluid significantly increased (P=-0.002) to a level higher than that in the PBC after G-CSF mobilization (P=0.004). Conclusion HLA-G plays an important role in immune tolerance after hematopoietic stem cell transplantation with G-CSF mobilization.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第12期2202-2203,共2页 Journal of Southern Medical University
基金 国家"863"高技术研究发展计划(2006AA02Z4A0) 广东省自然科学基金(7005160)
关键词 白细胞分化抗原 ALLO-HSCT 免疫耐受 human leukocyte antigen G allogenetic hematopoietic stem cell transplantation immune tolerance
  • 相关文献

参考文献5

  • 1Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-idantical sibling transplantation [J]. Blood, 2006, 107: 3065-73.
  • 2Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies [J]. Bone Marrow Transplant, 2006, 38: 291-7.
  • 3BensingerW I, Martin P J, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with hematologic cancers [J]. N Engl J Med, 2001, 344: 175-81.
  • 4Ji SQ, Chen HR, Wang HX, et al. Comparison of outcome of allogeneie bone marrow transplantation with and without granulocyte colony stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia [J]. Biol Blood Marrow Transplant, 2002, 8: 261-7.
  • 5Lindemanna M, Rebmann V, Ottinger HD, et al. rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors [J]. Exp Hematol, 2004, 32: 1103-9.

同被引文献26

  • 1李杭,陈颖娟,薛英波,杨飞月,徐方明.乳腺癌患者自体外周血干细胞移植时的动员及采集[J].贵阳医学院学报,2001,26(4):331-332. 被引量:1
  • 2Couban S, Simpson DR, Barnett M J, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling aUogeneic transplants for myeloid malignancies[J]. Blood, 2002, 100(5): 1525-31.
  • 3Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation [J]. Bone Marrow Transplant, 1998, 21(10): 995-1003.
  • 4Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle[J]. J Clin Oncol, 2000, 18(3): 537-46.
  • 5Bensinger WI, Martin P J, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers[J]. N Engl J Med, 2001, 344(3): 175-81.
  • 6Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid- cell-dependent tumour angiogenesis [J]. Nature, 2007, 450(7171): 825-31.
  • 7Shulman 'HM, Sullivan KM, Weiden PL, et al. Chronic grail-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients[J]. Am J Med, 1980, 69(2): 204-17.
  • 8Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading [J]. Bone Marrow Transplant, 1995, 15(6): 825-8.
  • 9Rodriguez PC, Ochra AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives[J]. Immunol Rev, 2008, 222(1): 180-91.
  • 10Gabrilovieh DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-74.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部